OOIR: Observatory of International Research

Papers

(The median citation count of Movement Disorders is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy	209
Meta‐Analysis of Gut Dysbiosis in Parkinson's Disease	198
Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease	177
Outcome of Parkinson's Disease Patients Affected by COVID‐19	176
Effects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study	139
Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease	127
Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID‐19 Pandemic	120
COVID‐19 in Parkinson’s Disease Patients Living in Lombardy, Italy	119
Impact of the COVID‐19 Pandemic on Parkinson's Disease and Movement Disorders	108
SARS‐CoV‐2: At the Crossroad Between Aging and Neurodegeneration	106
Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression	100
Genome‐Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease	99
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression	99
Coronavirus Disease 2019 and Parkinsonism: A Non‐post‐encephalitic Case	90
Parkinson's Disease and COVID‐19: Perceptions and Implications in Patients and Caregivers	88
Blinded RT‐QuIC Analysis of α‐Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients	85
Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders	83
Incidence of Anxiety in Parkinson's Disease During the Coronavirus Disease (COVID‐19) Pandemic	82
GBA‐Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort	81
Rapid Onset Functional Tic‐Like Behaviors in Young Females During the COVID‐19 Pandemic	81
GP2: The Global Parkinson's Genetics Program	76
Global Survey on Telemedicine Utilization for Movement Disorders During the COVID‐19 Pandemic	71
Integrated Care in Parkinson's Disease: A Systematic Review and Meta‐Analysis	70
Genotype–Phenotype Relations for Isolated Dystonia Genes: MDSGene Systematic Review	69
Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review	67

Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation	66
The Parkinson's Disease Genome‐Wide Association Study Locus Browser	66
Plasma Short‐Chain Fatty Acids in Patients With Parkinson's Disease	63
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease	62
Synaptic Loss in Primary Tauopathies Revealed by [¹¹C]UCB‐J Positron Emission Tomography	61
Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease	61
Validation of α‐Synuclein in L1CAM‐Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes	60
Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance	56
The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease	56
Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource	56
GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes	54
RT‐QuIC Detection of Pathological α‐Synuclein in Skin Punches of Patients with Lewy Body Disease	54
Closed‐Loop Deep Brain Stimulation for Essential Tremor Based on Thalamic Local Field Potentials	52
Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations	52
Differences in the Presentation and Progression of Parkinson's Disease by Sex	52
Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders	52
Pandemic Tic‐like Behaviors Following Social Media Consumption	51
Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease	51
International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease	51
Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum	50
A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy	50
Bilateral Focused Ultrasound Thalamotomy for Essential Tremor (BEST‐FUS Phase 2 Trial)	50
A Novel SNCA A30G Mutation Causes Familial Parkinsonʼs Disease	50
Coronavirus Disease 2019 Case Fatality and Parkinson's Disease	50
Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker	49
Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease	49
MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease	48
Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta‐Analysis	47
Skin Biopsy May Help to Distinguish Multiple System Atrophy–Parkinsonism from Parkinson's Disease With Orthostatic Hypotension	47
The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings	47
Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross‐Sectional Survey of 568 Spanish Patients	47
Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: A Kin Cohort Study	47
Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease	46
Cortical [¹⁸F]PI‐2620 Binding Differentiates Corticobasal Syndrome Subtypes	46
Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities	46
α‐Synuclein in Plasma‐Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease	45
Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug‐Naive Parkinson's Disease	45
GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10‐Year Population‐Based Study	45
Copathology in Progressive Supranuclear Palsy: Does It Matter?	45
European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies	44
Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial	44
Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force – An Update	44
Risk of Hospitalization and Death for COVID‐19 in People with Parkinson's Disease or Parkinsonism	43
Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms	41
Semiquantitative Scale for Assessing Brain MRI Abnormalities in Wilson Disease: A Validation Study	41
A Critical Review of White Matter Changes in Huntington’s Disease	41
Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study	40
Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease	40
Prevalence of Parkinson's Disease: A Community‐Based Study in China	40
A Large‐Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands	40

Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice	40
Clinical Utility of ¹⁸F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy	40
A Comprehensive Review of Brain Connectomics and Imaging to Improve Deep Brain Stimulation Outcomes	39
Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning	39
Dopamine Receptors in Parkinson's Disease: A Meta‐Analysis of Imaging Studies	38
The Possible Protective Role of α‐Synuclein Against Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Patients With Parkinson's Disease	38
The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α‐Synuclein in PD_GBA	38
Development and Validation of a Patient‐Reported Outcome Measure of Ataxia	38
Reduced Synaptic Density in Patients with Lewy Body Dementia: An [¹¹C]UCB‐J PET Imaging Study	38
Prodromal Spinocerebellar Ataxia Type 2 Subjects Have Quantifiable Gait and Postural Sway Deficits	37
Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease	37
In Vivo Assessment of Neuroinflammation in 4‐Repeat Tauopathies	36
Regional Brain and Spinal Cord Volume Loss in Spinocerebellar Ataxia Type 3	36
The Impact of COVID‐19 on Access to Parkinson's Disease Medication	36
Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease	36
Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease	36
Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease	36
Development of SARA^home, a New Video‐Based Tool for the Assessment of Ataxia at Home	36
Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach	36
A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders	35
A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait	35
Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs	35
Peripheral Immune Profile and Neutrophil‐to‐Lymphocyte Ratio in Parkinson's Disease	35
Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease	35
Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2‐Hydroxypropyl‐β‐Cyclodextrin Treatment	34
Clinical Profiles and Mortality of COVID‐19 Inpatients with Parkinson's Disease in Germany	34
Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta‐Analysis	34
CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories	34
Movement Disorder Society–Unified Parkinson's Disease Rating Scale Use in the Covid‐19 Era	34
Voice Analysis with Machine Learning: One Step Closer to an Objective Diagnosis of Essential Tremor	33
The Neurophysiology of Sleep in Parkinson's Disease	33
Cerebrospinal Fluid Cytokines and Neurodegeneration‐Associated Proteins in Parkinson's Disease	33
Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study	33
Abstracts	33
α‐Synuclein Spread from Olfactory Bulb Causes Hyposmia, Anxiety, and Memory Loss in BAC‐SNCA Mice	33
Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease	32
Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms	32
Dissecting the Phenotype and Genotype of PLA2G6‐Related Parkinsonism	32
Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder	32
Gait Variability in Spinocerebellar Ataxia Assessed Using Wearable Inertial Sensors	32
Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?	31
Genotype–Phenotype Relations in Primary Familial Brain Calcification: Systematic MDSGene Review	31
Diagnostic Value of Salivary Real‐Time Quaking‐Induced Conversion in Parkinson's Disease and Multiple System Atrophy	31
Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease	31
Seven Solutions for Neuroprotection in Parkinson's Disease	31
Brain Structural Changes in Focal Dystonia—What About Task Specificity? A Multimodal MRI Study	31
Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease	31
Covid‐19 Infection and Parkinsonism: Is There a Link?	31
Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism	30
Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed‐Start Analysis of the MOXIe Extension	30
Unmet Needs of Women Living with Parkinson's Disease: Gaps and Controversies	30
Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early‐Onset Parkinson's Disease	30
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers	30
Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease	30
Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset	30
The Impact of Type 2 Diabetes in Parkinson's Disease	30
Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures	30
The Gut Metabolite Trimethylamine N‐oxide Is Associated With Parkinson's Disease Severity and Progression	30
Impact of Coronavirus Disease 2019 Pandemic on Cognition in Parkinson's Disease	29
Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy	29
Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient‐Derived Neurons	29
Recent Advances in the Development of Stem‐Cell‐Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease	29
Abstracts of the MDS Virtual Congress 2021	29
Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach	28
Age at Onset of LRRK2 p.Gly2019Ser Is Related to Environmental and Lifestyle Factors	28
Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease	28
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals	28
Magnetic Resonance Imaging Biomarkers Distinguish Normal Pressure Hydrocephalus From Progressive Supranuclear Palsy	28
Resting‐State Functional Connectivity Predicts STN DBS Clinical Response	28
Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease	28
Four‐Year Follow‐up of [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography–Based Parkinson's Disease–Related Pattern Expression in 20 Patients with Isolated Rapid Eye Movement S	28
The Phenotypic and Genetic Spectrum of Paroxysmal Kinesigenic Dyskinesia in China	27
Parkinson's Disease Is Associated with Impaired Gut–Blood Barrier for Short‐Chain Fatty Acids	27
Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12‐Week, Randomized, Controlled Study	27
Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation	27
The Logic and Pitfalls of Parkinson's Disease as “Brain‐First” Versus “Body‐First” Subtypes	27
Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease	27
Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study	26
How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?	26
Treatment of *CSF1R*‐Related Leukoencephalopathy: Breaking New Ground	26

Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?	26
Functional Connectomics and Disease Progression in Drug‐Naïve Parkinson's Disease Patients	26
Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta‐Analysis	26
Laryngeal Movement Disorders in Multiple System Atrophy: A Diagnostic Biomarker?	26
Altered Cholinergic Innervation in De Novo Parkinson's Disease with and Without Cognitive Impairment	25
Is Levodopa Response a Valid Indicator of Parkinson's Disease?	25
Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy	25
Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting	25
Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease	25
A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease	25
Air Pollution and the Risk of Parkinson's Disease: A Review	25
High Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson's Disease	25
Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease	25
Highlighting the Dystonic Phenotype Related to GNAO1	25
Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment	25
CD4+ T‐cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson's Disease	25
Re‐emergent Tremor in Parkinson's Disease: The Role of the Motor Cortex	25
Dysregulated Brain Cholesterol Metabolism Is Linked to Neuroinflammation in Huntington's Disease	25
Levodopa‐Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial	24
Magnetic Susceptibility Associates With Dopaminergic Deficits and Cognition in Parkinson's Disease	24
Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression	24
Dynamics of Top‐Down Control and Motor Networks in Parkinson's Disease	24
Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease	24
RFC1 Intronic Repeat Expansions Absent in Pathologically Confirmed Multiple Systems Atrophy	24
Inflammation in Experimental Models of α‐Synucleinopathies	24
Once‐Weekly Subcutaneous Delivery of Polymer‐Linked Rotigotine (SER‐214) Provides Continuous Plasma Levels in Parkinson's Disease Patients	24
Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations	24
Cognitive Behavioral Therapy for Anxiety in Parkinsonʼs Disease: A Randomized Controlled Trial	24
Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of Leucine‐Rich Repeat Kinase 2 G2019S Carriers: A Novel Enzyme‐Linked Immunosorbent Assay–Base	24
GDNF/RET Signaling Pathway Activation Eliminates Lewy Body Pathology in Midbrain Dopamine Neurons	24
An Update on the Phenotype, Genotype and Neurobiology of ADCY5‐Related Disease	24
Olfactory Dysfunction in Recovered Coronavirus Disease 2019 (COVID‐19) Patients	24
Linking Parkinson's Disease and Melanoma: Interplay Between α‐Synuclein and Pmel17 Amyloid Formation	24
Timed Up and Go Test and the Risk of Parkinson's Disease: A Nation‐wide Retrospective Cohort Study	24
Juvenile‐Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review	23
Implementation of a Novel Bluetooth Technology for Remote Deep Brain Stimulation Programming: The Pre– and Post–COVID‐19 Beijing Experience	23
Clinical and Imaging Progression in the PARS Cohort: Long‐Term Follow‐up	23
Spinal Cord Stimulation for Very Advanced Parkinson's Disease: A 1‐Year Prospective Trial	23
Consensus Guidelines on Rodent Models of Restless Legs Syndrome	23
Telemedicine in Movement Disorders: Leçons du COVID‐19	23
Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study	23
A Chlorzoxazone‐Baclofen Combination Improves Cerebellar Impairment in Spinocerebellar Ataxia Type 1	23
Locus Coeruleus Integrity from 7 T MRI Relates to Apathy and Cognition in Parkinsonian Disorders	23
Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease	23
Dopamine D1 Receptors Regulate Spines in Striatal Direct‐Pathway and Indirect‐Pathway Neurons	23
Echo‐Focusing in Transcranial Focused Ultrasound Thalamotomy for Essential Tremor: A Feasibility Study	23
Gaps, Controversies, and Proposed Roadmap for Research in Normal Pressure Hydrocephalus	23
Real‐Life Turning Movements Capture Subtle Longitudinal and Preataxic Changes in Cerebellar Ataxia	23
α‐Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives	23
Striatal Blood–Brain Barrier Opening in Parkinson's Disease Dementia: A Pilot Exploratory Study	23
Movement Disorders in the World of COVID‐19	23
Neuroticism and Risk of Parkinson's Disease: A Meta‐Analysis	22
A Post‐COVID‐19 Parkinsonism in the Future?	22
Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK‐PD Study)	22
Online Mapping With the Deep Brain Stimulation Lead: A Novel Targeting Tool in Parkinson's Disease	22
Expanding Data Collection for the MDSGene Database: X‐linked Dystonia‐Parkinsonism as Use Case Example	22
Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study	22
Clinical Conditions “Suggestive of Progressive Supranuclear Palsy”—Diagnostic Performance	22
Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline	22
FDG‐PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome	22
White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease	22
Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease	22
In Vivo Molecular Signatures of Cerebellar Pathology in Spinocerebellar Ataxia Type 3	22
Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF‐α Pathway	22
DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism‐Dystonia	22
A Randomized, Placebo‐Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome	22
Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease	22
Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta‐Analytic Modeling	22
Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders	22
Functional Topography of the Human Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease	22
A Novel DBS Paradigm for Axial Features in Parkinson's Disease: A Randomized Crossover Study	21
Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression	21
Levodopa‐Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism	21
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity	21
Mutation Analysis of DNAJC Family for Early‐Onset Parkinson's Disease in a Chinese Cohort	21
Dietary Antioxidants and Risk of Parkinson's Disease in the Singapore Chinese Health Study	21
Aromatic L‐Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease	21
Polyglutamine‐Expanded Ataxin‐3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood	21
Idiopathic Non‐task‐Specific Upper Limb Dystonia, a Neglected Form of Dystonia	21
Perampanel Inhibits α‐Synuclein Transmission in Parkinson's Disease Models	21
Disruption of Brainstem Structural Connectivity in REM Sleep Behavior Disorder Using 7 Tesla Magnetic Resonance Imaging	21
Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity	21
A Double‐Blind, Randomized, Controlled Trial of Lovastatin in Early‐Stage Parkinson's Disease	21
Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population	21
Abstract	21
A Gain‐of‐Function Mutation in KCNMA1 Causes Dystonia Spells Controlled With Stimulant Therapy	21
Genotype–Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review	21
Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent‐Wide Survey	21
Profiling the Biochemical Signature of GBA‐Related Parkinson's Disease in Peripheral Blood Mononuclear Cells	21
A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation	20
Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives	20
Is Persistent Motor or Vocal Tic Disorder a Milder Form of Tourette Syndrome?	20
Striatal Dopamine Deficit and Motor Impairment in Idiopathic Normal Pressure Hydrocephalus	20
A Machine‐Learning Derived Huntington's Disease Progression Model: Insights for Clinical Trial Design	20
Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease	20